Luye Pharma GroupFRA:LUP +3.03%47 Quick Ratio is 1.44 as of Dec. 2025, which is 10% above its 10-year median of 1.31. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 996 Drug Manufacturers companies, Luye Pharma Group ranks worse than 50.2% on this metric.
Luye Pharma Group has a quick ratio of 1.44. It generally indicates good short-term financial strength.
The historical rank and industry rank for Luye Pharma Group's Quick Ratio or its related term are showing as below:
FRA:LUP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.99 Med: 1.31 Max: 2.03
Current: 1.44
During the past 13 years, Luye Pharma Group's highest Quick Ratio was 2.03. The lowest was 0.99. And the median was 1.31.
FRA:LUP's Quick Ratio is ranked worse than 50.2% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs FRA:LUP: 1.44
Luye Pharma Group (FRA:LUP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Luye Pharma Group Quick Ratio Related Terms
Luye Pharma Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Luye Pharma Group's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Quick Ratio of 1.44 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Luye Pharma Group and its competitors. This is 10% above median its historical median of 1.31. Over the past decade, Luye Pharma Group's Quick Ratio has ranged from 0.99 to 2.03. According to the industry distribution chart, Luye Pharma Group ranks #500 out of 996 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is Luye Pharma Group's Quick Ratio too high?
Luye Pharma Group's current Quick Ratio of 1.44 is 10% above median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 2.03. The Drug Manufacturers industry median Quick Ratio is 1.45. Luye Pharma Group's value of 1.44 is 0.7% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #500 out of 996 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #500 out of 996 companies for Quick Ratio. This places Luye Pharma Group in the lower half of its industry. The industry median Quick Ratio is 1.45. Luye Pharma Group's value of 1.44 is 0.7% below this benchmark. Historically, Luye Pharma Group's own Quick Ratio has ranged from 0.99 to 2.03 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 1.45, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Quick Ratio of 1.44 is 0.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Quick Ratio is 1.44, which is 10% above median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Quick Ratio is 1.44, which is 10% above median its 10-year median of 1.31 and 0.7% below the Drug Manufacturers industry median of 1.45. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Quick Ratio is 1.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Quick Ratio: 1.44 (10% above median its 10-year median of 1.31)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 0.7% below the Drug Manufacturers median (#500 of 996)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
